A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 378
Comprehensive Pages
- 35
Competitors Profiled
- 11
IOL Categories Forecasted
- 8
Geographic and Economic Breakouts
2025 IOL Market Report: Global Analysis for 2024 to 2030, March, 2025
The “2025 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 12 categories of IOLs: commodity monofocal, enhanced monofocal, intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, post-op adjustable, and phakic IOLs. Additionally, 35 companies are profiled, with discussion of their products, strategic market position, background, and outlook.
Latest Industry News & Trends
10/24/2025
BreakingDealsRefractiveSurgical
Alcon-STAAR Deal Up in the Air as Shareholder Vote is Delayed
STAAR Surgical adjourned until Nov. 6 the shareholder vote for its planned sale to Alcon during a virtual special meeting of shareholders on Oct. 23. Alcon made public on Aug. 5 its plans to purcha...
10/24/2025
BreakingCornealRegulation
US FDA Approves Glaukos’ Epioxa Epi-On Crosslinking Therapy for Keratoconus
Glaukos, of Aliso Viejo, California, reported Oct. 20 that the US FDA had approved Epioxa, an epi-on version of the company’s iLink corneal crosslinking therapy for keratoconus. Thomas Burns, Glauk...
10/24/2025
BreakingCataractIOLRevenueSurgical
J&J Vision Surgical Posts Q3-2025 Revenue of $383 Million
J&J Vision’s Q3-2025 global surgical vision revenue totaled $383 million, a 14.9 percent increase over $333 million in Q3-2024, parent Johnson & Johnson, of New Brunswick, New Jersey, reported Oct....
10/23/2025
ESCRSEuropeMeetingNewsletter
2025 ESCRS Congress Boasts Strong Attendance and Multiple Product Launches
More than 15 thousand people registered for the 2025 congress of the European Society of Cataract and Refractive Surgeons (ESCRS), held Sept. 12-16 at the Bella Center in Copenhagen, Denmark. Sixty...
10/24/2025
AIBreakingDealsDiagnosticOculomics
Topcon Healthcare to Acquire AI Screening Company Toku
Topcon Healthcare announced Oct. 17 that it had signed a definitive agreement to acquire Toku, an artificial intelligence (AI) health technology company originally founded in New Zealand. No financ...
10/24/2025
BreakingDealsPharmaRetina
Santen Acquires Rights in South Korea to Novartis’ Beovu and Lucentis
Santen Pharmaceutical announced Oct. 20 that it had acquired exclusive distribution rights in South Korea for Novartis’ retinal treatments Beovu (brolucizumab) and Lucentis (ranibizumab). Both Beov...
10/24/2025
BreakingChinaDealsGene TherapyRetina
AviadoBio Signs Option to License UgeneX’ Optogenetics Gene Therapy Candidate
UK-based AviadoBio announced Oct. 9 that it had signed an option agreement to license UGX-202, an AAV-based optogenetic treatment candidate targeting retinitis pigmentosa, from China’s UgeneX Thera...
10/24/2025
BreakingGene TherapyRegulationRetina
US FDA Selects Abeona’s XLRS Candidate for Rare Disease Endpoint Program
Abeona Therapeutics announced Oct. 13 that the US FDA had selected its ABO-503 gene therapy candidate for X-linked retinoschisis (XLRS) to participate in the Rare Disease Endpoint Advancement (RDEA...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.